Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo attack on rare cancer: immunotherapy joins chemo

NCT ID NCT05058651

Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 10 times

Summary

This trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (platinum drug plus etoposide) helps people with advanced or metastatic extrapulmonary neuroendocrine carcinoma live longer. About 189 participants will be randomly assigned to receive chemo alone or chemo plus atezolizumab, with some continuing atezolizumab beyond initial treatment. The goal is to see if the combination improves overall survival and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
atezolizumab (immunotherapy) plus platinum drug (cisplatin or carboplatin) and etoposide (chemotherapy)
What this could lead to
If it works, this combination could become a new standard first-line treatment, improving survival and tumor shrinkage for people with this rare, aggressive cancer.
What could go wrong
This is a phase II/III trial, so results are not yet proven. Adding immunotherapy may increase side effects like immune-related inflammation, and the benefit may be modest or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 189 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2022

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants must have histologically-confirmed (local site pathological confirmation sufficient) extrapulmonary poorly differentiated, neuroendocrine carcinoma (NEC) * Participants must have disease that is unresectable or metastatic and not eligible for definitive therapy as deemed per the treating investigator * Participants must have radiologically evaluable disease, measurable or non-measurable, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. All measurable and nonmeasurable lesions must be assessed by CT scan with IV contrast of the chest/abdomen/and pelvis (or CT chest without contrast and MRI abdomen/pelvis with gadolinium contrast, if contraindication to CT iodinated contrast) within 28 days prior to registration. While may be used for routine clinical evaluation, PET scans and bone scans alone are not acceptable for disease assessment while participating in this study. All known sites of disease must be assessed and documented on the Baseline Tumor Assessment Form * Participants must have brain MRI (or CT head with contrast if there is contraindication to MRI brain) if clinically indicated within 28 days prior to registration. Note: Brain imaging is not required in participants without known and/or clinical concern for brain metastases. Participants with asymptomatic central nervous system (CNS) metastases are eligible if one or more of the following apply: * Participants who have received treatment for brain metastases must have: * No evidence of radiological progression (by MRI brain or CT head with contrast if there is contraindication to MRI brain) within 28 days prior to registration * Discontinued all corticosteroids at least 14 days prior to registration * Participants with treatment-naive brain lesions must have: * No lesion measuring \> 2.0 cm in size in any axis * MRI brain or CT head with contrast (if there is contraindication to MRI brain) demonstrating no evidence for mass effect, edema, or other impending neurological compromise within 28 days prior to registration * No evidence of radiological progression (by MRI brain or CT head with contrast if there is contraindication to MRI brain) within 28 days prior to registration * No need for \> 2 mg of dexamethasone (or equivalent of \> 10 mg prednisone) per day at time of registration * Participants must not have symptomatic central nervous system (CNS) metastases * Participants must not have known or suspected leptomeningeal disease * Participants with prior history of non-metastatic (localized/locally advanced disease) extrapulmonary poorly differentiated NEC may have had prior platinum-based therapy +/- radiation +/- surgery provided that all therapy was completed \>= 6 months prior to registration * Participants must discontinue denosumab prior to study registration and plan to replace with a bisphosphonate while on the study * Participants must not have had prior treatment for advanced or metastatic NEC EXCEPT one cycle of platinum (carboplatin/cisplatin) + etoposide is allowed prior to registration. Other chemotherapy regimens are not allowed. For participants with prostate or urothelial NEC, prior chemotherapy for the non-NEC component (e.g. adenocarcinoma or urothelial) is allowed as long as such therapy was completed \>= 24 weeks prior to registration and participants have recovered from all prior toxicities to =\< grade 1. * Participants must not have had prior treatment with an anti-PD-1, anti-PD-L1, antiPD-L2, CD137 agonists, anti-CTLA-4 agent, or any other immune checkpoint inhibitors for any neuroendocrine neoplasm. Immune checkpoint inhibitors given for other cancer indications are allowed provided last therapy was given at least 12 months prior to study registration * Participants must not have received treatment with systemic immunostimulatory agents including, but not limited to, interferon and interleukin2 \[IL-2\] within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to registration * Participants must not have had history of known severe allergy, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies, including to Chinese hamster ovary cell products or to any component of the atezolizumab formulation, cisplatin, carboplatin, or etoposide * Participants must not be on active systemic therapy for another cancer with the exception of hormonal therapy including androgen deprivation therapy (e.g., gonadotropin-releasing hormone \[GnRH\] agonists or antagonists), which can be continued while participants are receiving protocol therapy. Use of enzalutamide or apalutamide is permitted after completion of chemotherapy and must be held during chemotherapy for participants receiving prior to enrollment. Use of darolutamide is permitted during chemotherapy. Glucocorticoid-containing regimens, including abiraterone, are not permitted. * Participants must be \>= 18 years of age * Participants must have a Zubrod performance status of =\< 2 within 28 days prior to registration * Participants must have a complete medical history and physical exam within 28 days prior to registration * Absolute neutrophil count (ANC) \>= 1.5 x 10\^9 /L (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests) * Hemoglobin \>= 9.0 g/dl (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests) * Platelet count \>= 100 x 10\^9/L (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests) * Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 2.5 x institutional upper limit of normal (ULN) (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests) * Serum total bilirubin =\< 1.5 x ULN (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests) * Adequate renal function as defined by any 1 of the following: 1) Measured creatinine clearance (CL) \> 50 mL/min OR 2) Calculated creatinine CL \> 50 mL/min by the Cockcroft-Gault formula OR by 24-hour urine collection for determination of creatinine clearance (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests) * Participants must not have uncontrolled or symptomatic hypercalcemia (\> 1.5 mmol/L ionized calcium or calcium \> 12 mg/dL or corrected serum calcium \> ULN) within 14 days prior to registration. Participants who have asymptomatic hypercalcemia are eligible provided that medical therapy to treat the hypercalcemia is planned * Participants must not have a diagnosis of immunodeficiency nor be receiving systemic steroid therapy (equivalent of \> 20 mg of hydrocortisone per day) or any other form of immunosuppressive therapy within 14 days prior to registration * Participants must not have active or history of autoimmune disease or immune deficiency, including, but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren syndrome, Guillain-Barre syndrome, or multiple sclerosis with the following exceptions: * Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study * Patients with controlled type 1 diabetes mellitus who are on an insulin regimen are eligible for the study * Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met: * Rash must cover \< 10% of body surface area * Disease is well controlled at baseline and requires only low-potency topical corticosteroids * No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months * Participants must not have history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. NOTE: History of radiation pneumonitis in the radiation field (fibrosis) is permitted * Participants must not have significant cardiovascular disease, such as New York Heart Association class II or greater cardiac disease, myocardial infarction within 3 months prior to registration, unstable arrythmias, or unstable angina * Participants must not have had a major surgical procedure other than for diagnosis within 28 days prior to registration. Participant must not plan to receive a major surgical procedure during the course of protocol treatment. NOTE: Patient port placement is not considered a major surgery * Participants must not have severe infections (i.e., Common Terminology Criteria for Adverse Events \[CTCAE\] grade \>= 2) at time of registration, including but not limited to hospitalization for complications for infection, bacteremia, or severe pneumonia * Participants must not have known active tuberculosis * Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load, with testing performed as clinically indicated * Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with active HCV infection who are currently on treatment must have an undetectable HCV viral load, with testing performed as clinically indicated * Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at time of registration and have undetectable HIV viral load within 6 months of registration * Participants must not have prior allogeneic bone marrow transplantation or solid organ transplant * Participants must not have received administration of a live, attenuated vaccine (e.g., FluMist \[registered trademark\]) within 28 days prior to initiation of study treatment, during treatment with atezolizumab, and not plan to receive for 5 months after the last dose of atezolizumab * Participants must not be pregnant due to the possibility of harm to the fetus. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method (with details provided as a part of the consent process) during the treatment period and for 5 months after the final dose of atezolizumab. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a sideeffect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen * Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System * Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced extrapulmonary neuroendocrine carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neuroendocrine carcinoma neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced extrapulmonary neuroendocrine carcinoma Metastatic extrapulmonary neuroendocrine carcinoma Recurrent extrapulmonary neuroendocrine carcinoma Unresectable extrapulmonary neuroendocrine carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    255 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Abbott-Northwestern Hospital

    Minneapolis, Minnesota, 55407, United States

  • Adams Cancer Center

    Gettysburg, Pennsylvania, 17325, United States

  • AdventHealth Littleton

    Littleton, Colorado, 80122, United States

  • AdventHealth Parker

    Parker, Colorado, 80138, United States

  • AdventHealth Porter

    Denver, Colorado, 80210, United States

  • Alaska Women's Cancer Care

    Anchorage, Alaska, 99508, United States

  • Allegiance Health

    Jackson, Michigan, 49201, United States

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California, 94704, United States

  • Atrium Health Cabarrus/LCI-Concord

    Concord, North Carolina, 28025, United States

  • Atrium Health Cleveland/LCI-Cleveland

    Shelby, North Carolina, 28150, United States

  • Atrium Health Pineville/LCI-Pineville

    Charlotte, North Carolina, 28210, United States

  • Atrium Health University City/LCI-University

    Charlotte, North Carolina, 28262, United States

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

    Houston, Texas, 77030, United States

  • Ben Taub General Hospital

    Houston, Texas, 77030, United States

  • Broadlawns Medical Center

    Des Moines, Iowa, 50314, United States

  • Bronson Battle Creek

    Battle Creek, Michigan, 49017, United States

  • Bronson Methodist Hospital

    Kalamazoo, Michigan, 49007, United States

  • California Pacific Medical Center-Pacific Campus

    San Francisco, California, 94115, United States

  • Cancer Care Associates of York

    York, Pennsylvania, 17403, United States

  • Cancer Care Center of O'Fallon

    O'Fallon, Illinois, 62269, United States

  • Cancer Care Specialists of Illinois - Decatur

    Decatur, Illinois, 62526, United States

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona, 85004, United States

  • Cancer Centers of Southwest Oklahoma Research

    Lawton, Oklahoma, 73505, United States

  • Cancer Hematology Centers - Flint

    Flint, Michigan, 48503, United States

  • Cancer and Hematology Centers of Western Michigan - Norton Shores

    Norton Shores, Michigan, 49444, United States

  • Carle BroMenn Medical Center

    Normal, Illinois, 61761, United States

  • Carle Cancer Center

    Urbana, Illinois, 61801, United States

  • Carle Cancer Institute Normal

    Normal, Illinois, 61761, United States

  • Carle Physician Group-Effingham

    Effingham, Illinois, 62401, United States

  • Carle Physician Group-Mattoon/Charleston

    Mattoon, Illinois, 61938, United States

  • Carle at The Riverfront

    Danville, Illinois, 61832, United States

  • Carolinas Medical Center/Levine Cancer Institute

    Charlotte, North Carolina, 28203, United States

  • Centralia Oncology Clinic

    Centralia, Illinois, 62801, United States

  • Chelsea Hospital

    Chelsea, Michigan, 48118, United States

  • Corewell Health Beaumont Troy Hospital

    Troy, Michigan, 48085, United States

  • Corewell Health Dearborn Hospital

    Dearborn, Michigan, 48124, United States

  • Corewell Health Farmington Hills Hospital

    Farmington Hills, Michigan, 48336, United States

  • Corewell Health Grand Rapids Hospitals - Butterworth Hospital

    Grand Rapids, Michigan, 49503, United States

  • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center

    Saint Joseph, Michigan, 49085, United States

  • Corewell Health Lakeland Hospitals - Niles Hospital

    Niles, Michigan, 49120, United States

  • Corewell Health Lakeland Hospitals - Saint Joseph Hospital

    Saint Joseph, Michigan, 49085, United States

  • Corewell Health Reed City Hospital

    Reed City, Michigan, 49677, United States

  • Corewell Health William Beaumont University Hospital

    Royal Oak, Michigan, 48073, United States

  • CoxHealth South Hospital

    Springfield, Missouri, 65807, United States

  • Crossroads Cancer Center

    Effingham, Illinois, 62401, United States

  • Dartmouth Cancer Center - North

    Saint Johnsbury, Vermont, 05819, United States

  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

    Lebanon, New Hampshire, 03756, United States

  • Decatur Memorial Hospital

    Decatur, Illinois, 62526, United States

  • Duke Cancer Center Cary

    Cary, North Carolina, 27518, United States

  • Duke Cancer Center Raleigh

    Raleigh, North Carolina, 27609, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • East Jefferson General Hospital

    Metairie, Louisiana, 70006, United States

  • Ephrata Cancer Center

    Ephrata, Pennsylvania, 17522, United States

  • Fairview Southdale Hospital

    Edina, Minnesota, 55435, United States

  • FirstHealth of the Carolinas-Moore Regional Hospital

    Pinehurst, North Carolina, 28374, United States

  • Fred Hutchinson Cancer Center

    Seattle, Washington, 98109, United States

  • Genesee Hematology Oncology PC

    Flint, Michigan, 48503, United States

  • Genesys Hurley Cancer Institute

    Flint, Michigan, 48503, United States

  • Greater Regional Medical Center

    Creston, Iowa, 50801, United States

  • Gundersen Lutheran Medical Center

    La Crosse, Wisconsin, 54601, United States

  • Hawaii Cancer Care - Westridge

    ‘Aiea, Hawaii, 96701, United States

  • Hawaii Cancer Care Inc - Waterfront Plaza

    Honolulu, Hawaii, 96813, United States

  • Hennepin County Medical Center

    Minneapolis, Minnesota, 55415, United States

  • Henry Ford Cancer Institute-Downriver

    Brownstown, Michigan, 48183, United States

  • Henry Ford Health Saint John Hospital

    Detroit, Michigan, 48236, United States

  • Henry Ford Health Warren Hospital

    Warren, Michigan, 48093, United States

  • Henry Ford Hospital

    Detroit, Michigan, 48202, United States

  • Henry Ford Macomb Hospital-Clinton Township

    Clinton Township, Michigan, 48038, United States

  • Henry Ford Madison Heights Hospital - Breast

    Warren, Michigan, 48093, United States

  • Henry Ford Medical Center-Columbus

    Novi, Michigan, 48377, United States

  • Henry Ford Medical Center-Fairlane

    Dearborn, Michigan, 48126, United States

  • Henry Ford River District Hospital

    East China Township, Michigan, 48054, United States

  • Henry Ford Saint John Hospital - Academic

    Grosse Pointe Woods, Michigan, 48236, United States

  • Henry Ford Saint John Hospital - Breast

    Grosse Pointe Woods, Michigan, 48236, United States

  • Henry Ford Saint John Hospital - Macomb Medical

    Macomb, Michigan, 48044, United States

  • Henry Ford Saint John Hospital - Van Elslander

    Grosse Pointe Woods, Michigan, 48236, United States

  • Henry Ford Warren Hospital - Breast Macomb

    Macomb, Michigan, 48044, United States

  • Henry Ford Warren Hospital - GLCMS

    Warren, Michigan, 48093, United States

  • Henry Ford West Bloomfield Hospital

    West Bloomfield, Michigan, 48322, United States

  • Henry Ford Wyandotte Hospital

    Wyandotte, Michigan, 48192, United States

  • Holy Cross Hospital

    Fort Lauderdale, Florida, 33308, United States

  • Huntsman Cancer Institute/University of Utah

    Salt Lake City, Utah, 84112, United States

  • Hurley Medical Center

    Flint, Michigan, 48503, United States

  • Huron Gastroenterology PC

    Ypsilanti, Michigan, 48106, United States

  • Ingalls Memorial Hospital

    Harvey, Illinois, 60426, United States

  • Iowa Methodist Medical Center

    Des Moines, Iowa, 50309, United States

  • Kaiser Permanente - Panorama City

    Panorama City, California, 91402, United States

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California, 90027, United States

  • Kaiser Permanente South Bay

    Harbor City, California, 90710, United States

  • Kaiser Permanente West Los Angeles

    Los Angeles, California, 90034, United States

  • Kaiser Permanente-Anaheim

    Anaheim, California, 92806, United States

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California, 91706, United States

  • Kaiser Permanente-Bellflower

    Bellflower, California, 90706, United States

  • Kaiser Permanente-Fontana

    Fontana, California, 92335, United States

  • Kaiser Permanente-Irvine

    Irvine, California, 92618, United States

  • Kaiser Permanente-Ontario

    Ontario, California, 91761, United States

  • Kaiser Permanente-Riverside

    Riverside, California, 92505, United States

  • Kaiser Permanente-San Diego Zion

    San Diego, California, 92120, United States

  • Kaiser Permanente-San Marcos

    San Marcos, California, 92078, United States

  • Kaiser Permanente-Woodland Hills

    Woodland Hills, California, 91367, United States

  • Karmanos Cancer Institute at McLaren Greater Lansing

    Lansing, Michigan, 48910, United States

  • LSU Health Baton Rouge-North Clinic

    Baton Rouge, Louisiana, 70805, United States

  • LSU Healthcare Network / Metairie Multi-Specialty Clinic

    Metairie, Louisiana, 70006, United States

  • Lahey Clinic

    Burlington, Massachusetts, 01805, United States

  • Lahey Clinic Peabody

    Peabody, Massachusetts, 01960, United States

  • Levine Cancer Institute-Ballantyne

    Charlotte, North Carolina, 28277, United States

  • Levine Cancer Institute-Gaston

    Gastonia, North Carolina, 28054, United States

  • Levine Cancer Institute-Rock Hill

    Rock Hill, South Carolina, 29732, United States

  • Levine Cancer Institute-SouthPark

    Charlotte, North Carolina, 28211, United States

  • Marshfield Medical Center - Minocqua

    Minocqua, Wisconsin, 54548, United States

  • Marshfield Medical Center - Weston

    Weston, Wisconsin, 54476, United States

  • Marshfield Medical Center-EC Cancer Center

    Eau Claire, Wisconsin, 54701, United States

  • Marshfield Medical Center-Marshfield

    Marshfield, Wisconsin, 54449, United States

  • Marshfield Medical Center-Rice Lake

    Rice Lake, Wisconsin, 54868, United States

  • Marshfield Medical Center-River Region at Stevens Point

    Stevens Point, Wisconsin, 54482, United States

  • Mary Greeley Medical Center

    Ames, Iowa, 50010, United States

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona, 85054, United States

  • Mayo Clinic in Florida

    Jacksonville, Florida, 32224-9980, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

  • McFarland Clinic - Ames

    Ames, Iowa, 50010, United States

  • McFarland Clinic - Boone

    Boone, Iowa, 50036, United States

  • McFarland Clinic - Jefferson

    Jefferson, Iowa, 50129, United States

  • McFarland Clinic - Marshalltown

    Marshalltown, Iowa, 50158, United States

  • McFarland Clinic - Trinity Cancer Center

    Fort Dodge, Iowa, 50501, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • Memorial Medical Center

    Modesto, California, 95355, United States

  • Mercy Cancer Center - Carmichael

    Carmichael, California, 95608, United States

  • Mercy Cancer Center - Elk Grove

    Elk Grove, California, 95758, United States

  • Mercy Cancer Center - Rocklin

    Rocklin, California, 95765, United States

  • Mercy Cancer Center - Sacramento

    Sacramento, California, 95816, United States

  • Mercy Cancer Center-West Lakes

    Clive, Iowa, 50325, United States

  • Mercy Hospital Joplin

    Joplin, Missouri, 64804, United States

  • Mercy Hospital Oklahoma City

    Oklahoma City, Oklahoma, 73120, United States

  • Mercy Hospital South

    St Louis, Missouri, 63128, United States

  • Mercy Hospital Springfield

    Springfield, Missouri, 65804, United States

  • Mercy Medical Center - Des Moines

    Des Moines, Iowa, 50314, United States

  • Mercy Medical Center-West Lakes

    West Des Moines, Iowa, 50266, United States

  • Mercy San Juan Medical Center

    Carmichael, California, 95608, United States

  • Minnesota Oncology - Burnsville

    Burnsville, Minnesota, 55337, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Mount Sinai Hospital

    New York, New York, 10029, United States

  • Munson Medical Center

    Traverse City, Michigan, 49684, United States

  • Northwestern Medicine Cancer Center Delnor

    Geneva, Illinois, 60134, United States

  • Northwestern Medicine Cancer Center Kishwaukee

    DeKalb, Illinois, 60115, United States

  • Northwestern Medicine Cancer Center Warrenville

    Warrenville, Illinois, 60555, United States

  • Northwestern Medicine Glenview Outpatient Center

    Glenview, Illinois, 60026, United States

  • Northwestern Medicine Grayslake Outpatient Center

    Grayslake, Illinois, 60030, United States

  • Northwestern Medicine Lake Forest Hospital

    Lake Forest, Illinois, 60045, United States

  • Northwestern Medicine Orland Park

    Orland Park, Illinois, 60462, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • Our Lady of the Lake Physician Group

    Baton Rouge, Louisiana, 70808, United States

  • Pali Momi Medical Center

    ‘Aiea, Hawaii, 96701, United States

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California, 94301, United States

  • Palo Alto Medical Foundation-Camino Division

    Mountain View, California, 94040, United States

  • Palo Alto Medical Foundation-Fremont

    Fremont, California, 94538, United States

  • Palo Alto Medical Foundation-Santa Cruz

    Santa Cruz, California, 95065, United States

  • Palo Alto Medical Foundation-Sunnyvale

    Sunnyvale, California, 94086, United States

  • Park Nicollet Clinic - Saint Louis Park

    Saint Louis Park, Minnesota, 55416, United States

  • Parkland Memorial Hospital

    Dallas, Texas, 75235, United States

  • Providence Cancer Institute Clackamas Clinic

    Clackamas, Oregon, 97015, United States

  • Providence Newberg Medical Center

    Newberg, Oregon, 97132, United States

  • Providence Portland Medical Center

    Portland, Oregon, 97213, United States

  • Providence Saint Vincent Medical Center

    Portland, Oregon, 97225, United States

  • Providence Willamette Falls Medical Center

    Oregon City, Oregon, 97045, United States

  • Queen's Cancer Cenrer - POB I

    Honolulu, Hawaii, 96813, United States

  • Queen's Cancer Center - Kuakini

    Honolulu, Hawaii, 96817, United States

  • Queen's Medical Center

    Honolulu, Hawaii, 96813, United States

  • Rapid City Regional Hospital

    Rapid City, South Dakota, 57701, United States

  • Regions Hospital

    Saint Paul, Minnesota, 55101, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • Rush-Copley Healthcare Center

    Yorkville, Illinois, 60560, United States

  • Rush-Copley Medical Center

    Aurora, Illinois, 60504, United States

  • Saint Alphonsus Cancer Care Center-Nampa

    Nampa, Idaho, 83687, United States

  • Saint Anthony Regional Hospital

    Carroll, Iowa, 51401, United States

  • Saint Charles Health System

    Bend, Oregon, 97701, United States

  • Saint Francis Medical Center

    Cape Girardeau, Missouri, 63703, United States

  • Saint Francis Regional Medical Center

    Shakopee, Minnesota, 55379, United States

  • Saint Luke's Hospital of Duluth

    Duluth, Minnesota, 55805, United States

  • Saint Vincent Frontier Cancer Center

    Billings, Montana, 59102, United States

  • Sechler Family Cancer Center

    Lebanon, Pennsylvania, 17042, United States

  • Smilow Cancer Hospital Care Center - Guilford

    Guilford, Connecticut, 06437, United States

  • Smilow Cancer Hospital Care Center - Waterford

    Waterford, Connecticut, 06385, United States

  • Smilow Cancer Hospital Care Center - Westerly

    Westerly, Rhode Island, 02891, United States

  • Smilow Cancer Hospital Care Center at Glastonbury

    Glastonbury, Connecticut, 06033, United States

  • Smilow Cancer Hospital Care Center at Greenwich

    Greenwich, Connecticut, 06830, United States

  • Smilow Cancer Hospital Care Center at Long Ridge

    Stamford, Connecticut, 06902, United States

  • Smilow Cancer Hospital Care Center at Saint Francis

    Hartford, Connecticut, 06105, United States

  • Smilow Cancer Hospital Care Center-Fairfield

    Fairfield, Connecticut, 06824, United States

  • Smilow Cancer Hospital Care Center-Trumbull

    Trumbull, Connecticut, 06611, United States

  • Smilow Cancer Hospital-Derby Care Center

    Derby, Connecticut, 06418, United States

  • Smilow Cancer Hospital-Torrington Care Center

    Torrington, Connecticut, 06790, United States

  • Smilow Cancer Hospital-Waterbury Care Center

    Waterbury, Connecticut, 06708, United States

  • Southeastern Medical Oncology Center-Clinton

    Clinton, North Carolina, 28328, United States

  • Southeastern Medical Oncology Center-Goldsboro

    Goldsboro, North Carolina, 27534, United States

  • Southeastern Medical Oncology Center-Jacksonville

    Jacksonville, North Carolina, 28546, United States

  • Southern Illinois University School of Medicine

    Springfield, Illinois, 62702, United States

  • Springfield Clinic

    Springfield, Illinois, 62702, United States

  • Springfield Memorial Hospital

    Springfield, Illinois, 62781, United States

  • Stony Brook University Medical Center

    Stony Brook, New York, 11794, United States

  • Straub Clinic and Hospital

    Honolulu, Hawaii, 96813, United States

  • Sutter Auburn Faith Hospital

    Auburn, California, 95602, United States

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California, 95603, United States

  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park

    Cameron Park, California, 95682, United States

  • Sutter Cancer Centers Radiation Oncology Services-Roseville

    Roseville, California, 95661, United States

  • Sutter Medical Center Sacramento

    Sacramento, California, 95816, United States

  • Sutter Pacific Medical Foundation

    Santa Rosa, California, 95403, United States

  • Sutter Roseville Medical Center

    Roseville, California, 95661, United States

  • Sutter Solano Medical Center/Cancer Center

    Vallejo, California, 94589, United States

  • The Queen's Medical Center - West Oahu

    ‘Ewa Beach, Hawaii, 96706, United States

  • Toledo Clinic Cancer Centers-Toledo

    Toledo, Ohio, 43623, United States

  • Trinity Health Grand Rapids Hospital

    Grand Rapids, Michigan, 49503, United States

  • Trinity Health IHA Medical Group Hematology Oncology - Brighton

    Brighton, Michigan, 48114, United States

  • Trinity Health IHA Medical Group Hematology Oncology - Canton

    Canton, Michigan, 48188, United States

  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

    Chelsea, Michigan, 48118, United States

  • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

    Ypsilanti, Michigan, 48197, United States

  • Trinity Health Medical Center - Brighton

    Brighton, Michigan, 48114, United States

  • Trinity Health Medical Center - Canton

    Canton, Michigan, 48188, United States

  • Trinity Health Muskegon Hospital

    Muskegon, Michigan, 49444, United States

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor

    Ann Arbor, Michigan, 48106, United States

  • Trinity Health Saint Joseph Mercy Oakland Hospital

    Pontiac, Michigan, 48341, United States

  • Trinity Health Saint Mary Mercy Livonia Hospital

    Livonia, Michigan, 48154, United States

  • UC Comprehensive Cancer Center at Silver Cross

    New Lenox, Illinois, 60451, United States

  • UChicago Medicine Northwest Indiana

    Crown Point, Indiana, 46307, United States

  • UI Health Care Mission Cancer and Blood - Ankeny Clinic

    Ankeny, Iowa, 50023, United States

  • UI Health Care Mission Cancer and Blood - Des Moines Clinic

    Des Moines, Iowa, 50309, United States

  • UI Health Care Mission Cancer and Blood - Laurel Clinic

    Des Moines, Iowa, 50314, United States

  • UI Health Care Mission Cancer and Blood - Waukee Clinic

    Waukee, Iowa, 50263, United States

  • UI Health Care Mission Cancer and Blood - West Des Moines Clinic

    Clive, Iowa, 50325, United States

  • UT Southwestern Clinical Center at Richardson/Plano

    Richardson, Texas, 75080, United States

  • UT Southwestern Simmons Cancer Center - RedBird

    Dallas, Texas, 75237, United States

  • UT Southwestern/Simmons Cancer Center-Dallas

    Dallas, Texas, 75390, United States

  • UT Southwestern/Simmons Cancer Center-Fort Worth

    Fort Worth, Texas, 76104, United States

  • UW Health Carbone Cancer Center Rockford

    Rockford, Illinois, 61114, United States

  • United Hospital

    Saint Paul, Minnesota, 55102, United States

  • United Hospital Center

    Bridgeport, West Virginia, 26330, United States

  • University Medical Center New Orleans

    New Orleans, Louisiana, 70112, United States

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois, 60637, United States

  • University of Chicago Medicine-Orland Park

    Orland Park, Illinois, 60462, United States

  • University of Hawaii Cancer Center

    Honolulu, Hawaii, 96813, United States

  • University of Michigan Health - West

    Wyoming, Michigan, 49519, United States

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48109, United States

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, 73104, United States

  • University of Washington Medical Center - Montlake

    Seattle, Washington, 98195, United States

  • Vanderbilt University/Ingram Cancer Center

    Nashville, Tennessee, 37232, United States

  • Wayne State University/Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Weisberg Cancer Treatment Center

    Farmington Hills, Michigan, 48334, United States

  • WellSpan Health-York Cancer Center

    York, Pennsylvania, 17403, United States

  • WellSpan Medical Oncology and Hematology

    Chambersburg, Pennsylvania, 17201, United States

  • West Michigan Cancer Center

    Kalamazoo, Michigan, 49007, United States

  • West Virginia University Healthcare

    Morgantown, West Virginia, 26506, United States

  • Woodland Memorial Hospital

    Woodland, California, 95695, United States

  • Yale University

    New Haven, Connecticut, 06520, United States

  • Yale-New Haven Hospital North Haven Medical Center

    North Haven, Connecticut, 06473, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.